Phenomix Corporation Initiates Phase 1a Clinical Trial of Hepatitis C Protease Inhibitor PHX1766

Published: Oct 28, 2008

SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company’s internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The study is being conducted at clinical sites in the Netherlands and will enroll approximately 24 healthy subjects and six HCV infected patients.

Back to news